Last Updated : May 20, 2025
Details
Generic Name:
roflumilast
Project Status:
Received
Therapeutic Area:
atopic dermatitis
Manufacturer:
Arcutis Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Zoryve
Project Line:
Reimbursement Review
Project Number:
SR0887-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For
topical treatment of mild to moderate atopic dermatitis in patients 6 years of
age and older, with inadequate response, intolerance, or contraindications to
topical corticosteroids
Submission Type:
Initial
Submission Complexity:
Standard Review
Fee Schedule:
Pending
Indications:
For
topical treatment of mild to moderate atopic dermatitis in patients 6 years of
age and older.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | April 03, 2025 |
|---|---|
| Call for patient/clinician input closed | May 27, 2025 |
| Submission received | May 16, 2025 |
| Submission accepted | - |
Last Updated : May 20, 2025